ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
6.70
+0.44 (7.03%)
At close: Nov 18, 2026, 4:00 PM EST
6.70
0.00 (0.00%)
Pre-market: Nov 19, 2026, 8:37 AM EST
ImmunityBio Revenue
ImmunityBio had revenue of $48.84M in the quarter ending September 30, 2026, with 52.34% growth. This brings the company's total for the last twelve months to $182.57M, up 121.15% year-over-year. In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth. That makes ImmunityBio the 18,164th largest company in the world by revenue and 2,930th in the United States.
Revenue (ttm)
$182.57M
Revenue Growth
+121.15%
P/S Ratio
39.04
Revenue / Employee
$264,214
Employees
691
Market Cap
7.13B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full ImmunityBio breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.29M | 98.54M | 668.31% |
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | 2.20M | 2.16M | 4,585.11% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | 1.00K | 2.27% |
| Dec 31, 2016 | 44.00K | -192.00K | -81.36% |
| Dec 31, 2015 | 236.00K | -405.00K | -63.18% |
| Dec 31, 2014 | 641.00K | 41.00K | 6.83% |
| Dec 31, 2013 | 600.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 1.05B |
| Axsome Therapeutics | 865.27M |
| Mirum Pharmaceuticals | 670.78M |
| Twist Bioscience | 459.43M |
| Arrowhead Pharmaceuticals | 450.82M |
| Ligand Pharmaceuticals | 253.83M |
| ABIVAX Société Anonyme | 5.33M |
IBRX News
- 3 days ago - ImmunityBio Transcript: Jefferies Global Healthcare Conference - Transcripts
- 3 days ago - ImmunityBio Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 8 days ago - ImmunityBio announces findings from survey of military members with NMIBC - TheFly
- 8 days ago - New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care - Business Wire
- 8 days ago - ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 - Business Wire
- 9 days ago - ImmunityBio falls -18.3% - TheFly
- 9 days ago - ImmunityBio falls -22.6% - TheFly
- 10 days ago - ImmunityBio reports Q3 EPS (18c), consensus (8c) - TheFly